For Immediate Release
Chicago, IL – December 20, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AstraZeneca (AZN), Mylan Pharma (MYL), Novartis (NVS), Teva Pharmaceuticals (TEVA) and Merck (MRK).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Wednesday’s Analyst Blog:
Good News for AstraZeneca
AstraZeneca (AZN) recently received some positive news when the Court of Appeals for the Federal Circuit maintained an earlier ruling that the US substance patent (RE37, 314) related to Crestor (rosuvastatin calcium) is valid. The ‘314 patent is set to expire in 2016, until which no generic version of Crestor will be approved by the US Food and Drug Administration (:FDA).
Several generic drug makers including Apotex, Aurobindo, Cobalt, Glenmark, Mylan Pharma (MYL), Sandoz, the generic arm of Novartis (NVS), Teva Pharmaceuticals (TEVA) and Torrent had submitted Abbreviated New Drug Applications (ANDAs) seeking approval for their generic versions of Crestor. These companies can now approach the US Supreme Court for rehearing.
Crestor is the lead revenue grosser at AstraZeneca. It currently faces stiff competition given the presence of Merck’s (MRK) Zocor/Vytorin and others.
Meanwhile, several products in AstraZeneca’s portfolio are already facing or are likely to face generic competition. In 2011, the company lost revenues worth almost $2 billion, to generic competition. The weak late-stage pipeline coupled with the slow Brilinta uptake also bothers us.
In such a scenario, we feel additional competition in the form of Crestor generic would have hit the top-line significantly. We believe that the court ruling in favor of AstraZeneca removes the uncertainty regarding entry of generics and is a positive for the company.
Currently, we have a Neutral stance on AstraZeneca in the long run. The stock carries a Zacks #3 Rank (Hold) in the short run.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com